Amgen Inc. said Monday it had agreed to sell two of its smaller drugs and license a third to Swedish drugmaker Biovitrum AB in a deal valued at $130 million. Stockholm-based Biovitrum will acquire ...

Amgen’s product sales grew by 2% in the first quarter, with 14% volume growth weighed down by lower prices (5% impact), lower wholesaler inventories, and foreign exchange headwinds.

As for Amgen’s stalwarts, osteoporosis treatment Prolia had an 8% increase year over year to $1 billion. Meanwhile, rheumatoid arthritis drug Enbrel—which is one of 10 products identified for ...

By Paul Ziobro Amgen posted 11% revenue growth in the fourth quarter, with at least double-digit growth from ten products. The biotechnology company on Tuesday reported a profit of $627 million ...